CN Patent

CN108779108A — 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途

Assigned to Astex Therapeutics Ltd · Expires 2018-11-09 · 8y expired

What this patent protects

本发明涉及式(I)和式(II)化合物,其中B为苯并三唑基、苯基、三唑并吡啶基或‑(CH 2 ) 2 三唑基,其各自可为未取代的或被1、2或3个独立地选自以下的取代基所取代:–C 1‑3 烷基、‑O‑C 1‑3 烷基、CN、‑(CH 2 ) 2 –O–(CH 2 ) 2 ‑OR 4 和卤素;D为–C(O)OH、‑C(O)NHSO 2 CH 3 、–SO 2 NHC(O)CH 3 、5‑(三氟甲基)‑4H‑1,2,4‑三唑‑2‑基或四唑基;以及它们作为NRF2调节剂的用途。

USPTO Abstract

本发明涉及式(I)和式(II)化合物,其中B为苯并三唑基、苯基、三唑并吡啶基或‑(CH 2 ) 2 三唑基,其各自可为未取代的或被1、2或3个独立地选自以下的取代基所取代:–C 1‑3 烷基、‑O‑C 1‑3 烷基、CN、‑(CH 2 ) 2 –O–(CH 2 ) 2 ‑OR 4 和卤素;D为–C(O)OH、‑C(O)NHSO 2 CH 3 、–SO 2 NHC(O)CH 3 、5‑(三氟甲基)‑4H‑1,2,4‑三唑‑2‑基或四唑基;以及它们作为NRF2调节剂的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN108779108A
Jurisdiction
CN
Classification
Expires
2018-11-09
Drug substance claim
No
Drug product claim
No
Assignee
Astex Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.